Vonoprazan/amoxicillin: Difference between revisions

Latest revision as of 22:04, 16 February 2025

Vonoprazan/Amoxicillin is a combination therapy used in the treatment of Helicobacter pylori infections. This combination includes Vonoprazan, a potassium-competitive acid blocker (P-CAB), and Amoxicillin, a penicillin antibiotic.

Vonoprazan[edit]

Vonoprazan is a novel P-CAB that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in the stomach lining. It is used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), and as part of the eradication therapy for Helicobacter pylori infections.

Amoxicillin[edit]

Amoxicillin is a broad-spectrum penicillin antibiotic that works by inhibiting the synthesis of bacterial cell walls. It is used in the treatment of a variety of bacterial infections, including those caused by Helicobacter pylori.

Combination Therapy[edit]

The combination of Vonoprazan and Amoxicillin is used in the eradication of Helicobacter pylori infections. The acid-suppressing effect of Vonoprazan creates an environment in the stomach that enhances the effectiveness of Amoxicillin against the bacteria.

Clinical Use[edit]

The Vonoprazan/Amoxicillin combination is typically administered twice daily for a period of 7 to 14 days, depending on the severity of the infection and the patient's response to therapy. The eradication rate of Helicobacter pylori with this combination therapy has been reported to be higher than that of traditional proton pump inhibitor (PPI)/Amoxicillin therapy.

Side Effects[edit]

Common side effects of the Vonoprazan/Amoxicillin combination include diarrhea, nausea, and skin rash. Serious side effects are rare but can include severe allergic reactions and Clostridium difficile associated diarrhea.

@@ Line 29: / Line 29: @@
 {{antibiotics-stub}}
 {{gastroenterology-stub}}
+<gallery>
+File:Vonoprazan_and_amoxicillin.svg|Vonoprazan and amoxicillin
+</gallery>